¿ Abgenix Inc., of Fremont, Calif., sold 208,000 shares of common stock at $15 per share, pursuant to the overallotment option that was part of an offering in March. Total proceeds of the offering before commissions and expenses were $48.1 million. (See BioWorld Today, March 5, 1999, p. 1.)
¿ Algene Biotechnologies Corp., of Montreal, and Myriad Genetics Inc., of Salt Lake City, cancelled by mutual agreement their non-binding deal disclosed Jan. 19, 1999. The deal would have provided Algene with about C$5 million (US$3.3 million) for Algene to pursue research on three disorders defined by Myriad. (See BioWorld Today, Jan. 21, 1999, p. 1.)
¿ Amarillo Biosciences Inc., of Amarillo, Texas, opened enrollment for the final Phase III clinical trial of the use of low-dose oral interferon for the treatment of dry mouth in Sjogren¿s syndrome patients. The trial is being conducted at 50 sites in the U.S., and completion of enrollment is expected in 1999. The company began two Phase III studies late last year. (See BioWorld Today, Nov. 25, 1998, p. 1.)
¿ Cellomics Inc., of Pittsburgh, and Molecular Probes Inc., of Eugene, Ore., entered into an agreement granting Cellomics exclusive rights to key Molecular Probes fluorescence technologies and products for use in Cellomics¿ high-content cell-based drug discovery technologies. Financial terms were not disclosed.
¿ Centocor Inc., of Malvern, Pa., entered a manufacturing agreement with Covance, of Princeton, N.J., to manufacture Centocor¿s Retavase (recombinant reteplase) for the U.S. and Canada. Retavase is a fibrinolytic for acute myocardial infarction.
¿ Lynx Therapeutics Inc., of Hayward, Calif., said it activated an earlier agreement with Hoechst Marion Roussel Inc., of Frankfurt, Germany, and the latter¿s affiliate, Hoechst Schering AgrEvo GmbH, to access Lynx¿s gene-analysis technologies through subscriptions. Lynx gets $2 million for non-exclusive access, plus a minimum payment of $2 million per year. The subscription may be extended for up to three years beyond the one-year period.
¿ OrthoLogic Corp., of Tempe, Ariz., said a Federal District Court has dismissed all claims against the company in a class-action suit that has been pending in the District of Arizona since 1996. Specific narrow claims against current and former officers still are pending.
¿ Phytera Inc., of Worcester, Mass., has received a Phase I Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to develop new tools for antibacterial drug discovery.
¿ RiboGene Inc., of Hayward, Calif., said its intranasal metaclopromide product, Emitasol, has been launched in Italy. The approved indications include treatment of nausea and vomiting induced by chemotherapy; functional non-ulcer dyspepsia; gastro-esophageal reflux; duodenal-gastric biliary reflux; gastroparesis of various origins; nausea and vomiting due to surgery or anesthetics; and gastric manifestations related to radiation sickness and cobalt therapy.